Short-term Antibiotic Therapy for Pyelonephritis in Childhood (STUTI)
|ClinicalTrials.gov Identifier: NCT00724256|
Recruitment Status : Terminated (other upcoming studies; patients refusal of invasive follow up (DMSA))
First Posted : July 29, 2008
Last Update Posted : February 17, 2012
The purpose of this study is to evaluate the efficacy of oral ceftibuten for 7 days versus 10 days in acute pyelonephritis in children.
The main hypothesis is that the ceftibuten for 7 days will be not inferior to ceftibuten 10 days in the rate of renal scarring at 6-12 months.
|Condition or disease||Intervention/treatment||Phase|
|Pyelonephritis||Drug: ceftibuten||Phase 3|
Acute pyelonephritis is one of the most common serious bacterial infections in childhood, particularly in young children, with an estimated prevalence in febrile infants of 5.3%. It has been considered an important risk factor for the development of renal scarring, and renal insufficiency. More recently the long term outcomes of pyelonephritis has ameliorated, probably because of prompt diagnosis and therapy, and the importance of urinary tract infection as a risk factor for renal insufficiency has been questioned.
Nevertheless, the optimal type and duration of antibiotic therapy for acute uncomplicated pyelonephritis in children is not established yet.
There is a general agreement that children who are dehydrated, unable to drink, or in whom sepsis is possible, should be admitted to hospital for intravenous antibiotic treatment.
Outside this conditions, evidence suggest that children with acute pyelonephritis can be treated effectively with cefixime, ceftibuten or amoxycillin/clavulanic acid. given orally (1).
A recently updated Cochrane review on antibiotic treatment for acute pyelonephritis in children identified twenty three studies (3407 children). No significant differences were found in persistent renal damage at six to 12 months (824 children: RR 0.80, 95% CI 0.50 to 1.26) or in duration of fever (808 children: WMD 2.05, 95% CI -0.84 to 4.94) between oral antibiotic therapy (10 to 14 days) and IV therapy (3 days) followed by oral therapy (10 days). Similarly no significant differences in persistent renal damage (3 studies, 341 children: RR 1.13, 95% CI 0.86 to 1.49) were found between IV therapy (3 to 4 days) followed by oral therapy and IV therapy for 7 to 14 days.
Authors concluded that children with acute pyelonephritis can be treated effectively with oral antibiotics (cefixime, ceftibuten and amoxycillin/clavulanic acid) or with short courses (2 to 4 days) of IV therapy followed by oral therapy.
Oral treatment also is easier to use and does not require admission to hospital, leading to reduced costs.
Nevertheless, the exact duration of oral therapy is not established. Current guidelines recommend 7-14 days course of broad-spectrum antibiotics capable of reaching significant renal levels.
The objective of our study is to evaluate if oral ceftibuten for 7 days is equally effective as oral ceftibuten for 10 days in acute pyelonephritis in children.
This is a non-inferiority randomised controlled trial to determine whether a short term therapy with ceftibuten ( 7 days) will be therapeutically similar to a long term therapy ( 10 days), measuring as major outcome the prevalence of renal scars.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood.|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2010|
ceftibuten 9mg/kg once a day for 7 days.
|Active Comparator: 2||
ceftibuten 9mg/kg once a day for 10 days.
- Rate of renal SCAR [ Time Frame: 6-12 month from urinary tract infection ]
- Relapses [ Time Frame: up to12 months ]
- Adverse effects of drug therapy [ Time Frame: 10 days ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00724256
|Institute for Child Health Burlo Garofolo|
|Triest, Italy, 34137|
|Study Director:||Marzia Lazzerini, MD DTMH||IRCCS Burlo Garofolo|